{"count": 5, "results": [{"_id": "36286721", "pmid": 36286721, "title": "[Advantages of the use of metformin in patients with impaired uric acid metabolism].", "journal": "Ter Arkh", "authors": ["Eliseev MS", "Panevin TS", "Zhelyabina OV", "Nasonov EL"], "date": "2021-05-15T00:00:00Z", "doi": "10.26442/00403660.2021.05.200795", "meta_date_publication": "2021 May 15", "meta_volume": "93", "meta_issue": "5", "meta_pages": "71520", "score": 50257.523, "text_hl": "Current data suggest that the mechanism of action of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ contributes to the development of an anti-@DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ effect, as well as a decrease in the level of @CHEMICAL_Uric_Acid @CHEMICAL_MESH:D014527 @@@uric acid@@@, and its use can be potentially useful in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Hyperuricemia</m> @DISEASE_MESH:D033461 @@@hyperuricemia@@@ and @DISEASE_Gout @DISEASE_MESH:D006073 @@@gout@@@.", "citations": {"NLM": "Eliseev MS, Panevin TS, Zhelyabina OV, Nasonov EL. [Advantages of the use of metformin in patients with impaired uric acid metabolism]. Ter Arkh. 2021 May 15;93(5):71520. PMID: 36286721", "BibTeX": "@article{36286721, title={[Advantages of the use of metformin in patients with impaired uric acid metabolism].}, author={Eliseev MS and Panevin TS and Zhelyabina OV and Nasonov EL}, journal={Ter Arkh}, volume={93}, number={5}, pages={71520}}"}}, {"_id": "33108744", "pmid": 33108744, "title": "Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: role of AMPK/SIRT1 activation and DPP-4 inhibition.", "journal": "Can J Physiol Pharmacol", "authors": ["Wahba NS", "Ghareib SA", "Abdel-Ghany RH", "Abdel-Aal M", "Alsemeh AE"], "date": "2021-06-01T00:00:00Z", "doi": "10.1139/cjpp-2020-0435", "meta_date_publication": "2021 Jun", "meta_volume": "99", "meta_issue": "6", "meta_pages": "685-697", "score": 50243.66, "text_hl": "In conjunction with the same concentrations of @CHEMICAL_Fructose @CHEMICAL_MESH:D005632 @@@fructose@@@ and @CHEMICAL_Salts @CHEMICAL_MESH:D012492 @@@salt@@@ feeding, @DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@MetS@@@ @SPECIES_10116 @@@rats@@@ with significant @DISEASE_Weight_Gain @DISEASE_MESH:D015430 @@@weight gain@@@, @DISEASE_Dyslipidemias @DISEASE_MESH:D050171 @@@dyslipidemia@@@, @<m>DISEASE_Hyperuricemia</m> @DISEASE_MESH:D033461 @@@hyperuricemia@@@, and dysglycemia were treated orally with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (200 mg/kg), @CHEMICAL_Cholecalciferol @CHEMICAL_MESH:D002762 @@@vitamin D3@@@ (10 microg/kg), or both daily for 6 weeks. ", "citations": {"NLM": "Wahba NS, Ghareib SA, Abdel-Ghany RH, Abdel-Aal M, Alsemeh AE. Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: role of AMPK/SIRT1 activation and DPP-4 inhibition. Can J Physiol Pharmacol. 2021 Jun;99(6):685-697. PMID: 33108744", "BibTeX": "@article{33108744, title={Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: role of AMPK/SIRT1 activation and DPP-4 inhibition.}, author={Wahba NS and Ghareib SA and Abdel-Ghany RH and Abdel-Aal M and Alsemeh AE}, journal={Can J Physiol Pharmacol}, volume={99}, number={6}, pages={685-697}}"}}, {"_id": "1009748", "pmid": 1009748, "title": "[Changes induced by various drugs (allopurinol, metformin) in various dysmetabolic components of primary hyperuricemia].", "journal": "Clin Ter", "authors": ["Butturini U", "Coscelli C", "Zavaroni I", "Lugari R", "Bobbioni E"], "date": "1976-06-30T00:00:00Z", "meta_date_publication": "1976 Jun 30", "meta_volume": "77", "meta_issue": "6", "meta_pages": "529-41", "score": 50070.383, "text_hl": "[Changes induced by various drugs (@CHEMICAL_Allopurinol @CHEMICAL_MESH:D000493 @@@allopurinol@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@) in various dysmetabolic components of primary @<m>DISEASE_Hyperuricemia</m> @DISEASE_MESH:D033461 @@@hyperuricemia@@@].", "citations": {"NLM": "Butturini U, Coscelli C, Zavaroni I, Lugari R, Bobbioni E. [Changes induced by various drugs (allopurinol, metformin) in various dysmetabolic components of primary hyperuricemia]. Clin Ter. 1976 Jun 30;77(6):529-41. PMID: 1009748", "BibTeX": "@article{1009748, title={[Changes induced by various drugs (allopurinol, metformin) in various dysmetabolic components of primary hyperuricemia].}, author={Butturini U and Coscelli C and Zavaroni I and Lugari R and Bobbioni E}, journal={Clin Ter}, volume={77}, number={6}, pages={529-41}}"}}, {"_id": "30488476", "pmid": 30488476, "title": "Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies.", "journal": "Biopharm Drug Dispos", "authors": ["Zhang G", "Ma Y", "Xi D", "Rao Z", "Sun X", "Wu X"], "date": "2019-01-01T00:00:00Z", "doi": "10.1002/bdd.2164", "meta_date_publication": "2019 Jan", "meta_volume": "40", "meta_issue": "1", "meta_pages": "3-11", "score": 50051.426, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is always used as the baseline antidiabetic therapy for @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@ (@DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@) and @<m>DISEASE_Hyperuricemia</m> @DISEASE_MESH:D033461 @@@hyperuricemia@@@. ", "citations": {"NLM": "Zhang G, Ma Y, Xi D, Rao Z, Sun X, Wu X. Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies. Biopharm Drug Dispos. 2019 Jan;40(1):3-11. PMID: 30488476", "BibTeX": "@article{30488476, title={Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies.}, author={Zhang G and Ma Y and Xi D and Rao Z and Sun X and Wu X}, journal={Biopharm Drug Dispos}, volume={40}, number={1}, pages={3-11}}"}}, {"_id": "31278727", "pmid": 31278727, "title": "Report: Metformin potential in predisposing arthralgia, type II cross reactivity secondary to group A streptococcus infection & other comorbidities in treating PCOS.", "journal": "Pak J Pharm Sci", "authors": ["Ayub M", "Gul S", "Zehra F"], "date": "2019-05-01T00:00:00Z", "meta_date_publication": "2019 May", "meta_volume": "32", "meta_issue": "3", "meta_pages": "1107-1110", "score": 50043.297, "text_hl": "Here, we present a case of a female diagnosed with @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@ who after treatment with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for more than two years, reported with @<m>DISEASE_Hyperuricemia</m> @DISEASE_MESH:D033461 @@@hyperuricemia@@@, @DISEASE_Migraine_Disorders @DISEASE_MESH:D008881 @@@migraine@@@, @DISEASE_Pain @DISEASE_MESH:D010146 @@@neurological pain@@@, severe @DISEASE_Shoulder_Pain @DISEASE_MESH:D020069 @@@joint and knee pains on shoulders and legs@@@, and @DISEASE_Rheumatic_Fever @DISEASE_MESH:D012213 @@@rheumatic fever@@@. ", "citations": {"NLM": "Ayub M, Gul S, Zehra F. Report: Metformin potential in predisposing arthralgia, type II cross reactivity secondary to group A streptococcus infection & other comorbidities in treating PCOS. Pak J Pharm Sci. 2019 May;32(3):1107-1110. PMID: 31278727", "BibTeX": "@article{31278727, title={Report: Metformin potential in predisposing arthralgia, type II cross reactivity secondary to group A streptococcus infection & other comorbidities in treating PCOS.}, author={Ayub M and Gul S and Zehra F}, journal={Pak J Pharm Sci}, volume={32}, number={3}, pages={1107-1110}}"}}]}